Literature DB >> 28294070

Dutasteride in Androgenetic Alopecia: An Update.

Tasleem Arif1, Konchok Dorjay2, Mohammad Adil2, Marwa Sami3.   

Abstract

BACKGROUND: Androgenetic alopecia is a common condition characterized by thinning of scalp hair. Conversion of testosterone to dihydrotestosterone, a more potent androgen, by the enzyme 5-α-reductase is responsible for underlying pathogenesis. Dutasteride, a synthetic 4-azasteroid, is a selective and competitive inhibitor of both type-1 and type-2 isoenzymes of 5-α-reductase. Finasteride and minoxidil are the only approved drugs for androgenetic alopecia. Dutasteride has been demonstrated to be effective in several randomized, double-blind, placebo controlled trials in androgenetic alopecia. In this review, after the pharmacology of dutasteride, the authors have discussed the status of dutasteride in androgenetic alopecia and have compared its efficacy with that of finasteride.
OBJECTIVE: This article aims to review the current status of dutasteride in androgenetic alopecia. The structure, mechanism of action, pharmacokinetics and side effects are discussed along with its comparison with finasteride in androgenetic alopecia.
METHOD: The main sources of our information were Medline Pubmed, Google scholar and Scopus including original articles and review articles. The keywords 'dutasteride', 'dutasteride in androgenetic alopecia' were used for search.
CONCLUSION: Like finasteride, dutasteride is now becoming popular treatment option in AGA, due to its good response shown by various randomized control studies and meta-analysis. Also, in most of these studies, dutasteride was found to be better than finasteride with comparable adverse effects. Therefore, dutasteride could become a treatment of choice for AGA in near future. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  5-α-reductase; Androgenetic alopecia; dihydrotestosterone; dutasteride; finasteride; minoxidil; testosterone

Mesh:

Substances:

Year:  2017        PMID: 28294070     DOI: 10.2174/1574884712666170310111125

Source DB:  PubMed          Journal:  Curr Clin Pharmacol        ISSN: 1574-8847


  7 in total

1.  [Therapeutic effect of Impatiens balsamina, Lawsonia inermis L. and Henna on androgenetic alopecia in mice].

Authors:  Yushi Zheng; Yongxuan Hu; Kangxing Liu; Yan Lu; Yanqing Hu; Xianyi Zhou
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-11-30

Review 2.  Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics.

Authors:  Mark S Nestor; Glynis Ablon; Anita Gade; Haowei Han; Daniel L Fischer
Journal:  J Cosmet Dermatol       Date:  2021-11-06       Impact factor: 2.189

3.  Nanoporous Silica Entrapped Lipid-Drug Complexes for the Solubilization and Absorption Enhancement of Poorly Soluble Drugs.

Authors:  Hey-Won Shin; Joo-Eun Kim; Young-Joon Park
Journal:  Pharmaceutics       Date:  2021-01-06       Impact factor: 6.321

Review 4.  Perspectives on miRNAs Targeting DKK1 for Developing Hair Regeneration Therapy.

Authors:  Dimitri Papukashvili; Nino Rcheulishvili; Cong Liu; Fengfei Xie; Deependra Tyagi; Yunjiao He; Peng George Wang
Journal:  Cells       Date:  2021-10-30       Impact factor: 6.600

Review 5.  Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: a review.

Authors:  Kornelia Pietrauszka; Beata Bergler-Czop
Journal:  Postepy Dermatol Alergol       Date:  2020-10-16       Impact factor: 1.664

Review 6.  Traditional Chinese Medicine Treatment for Androgenetic Alopecia Based on Animal Experiments: A Systematic Review and Meta-Analysis.

Authors:  Yanbo Liang; Jing Yuan; Nururshopa Eskander Shazada; Jun Jiang; Jianlin Wu
Journal:  Evid Based Complement Alternat Med       Date:  2022-10-11       Impact factor: 2.650

7.  In Vitro and In Vivo Assessment of Metabolic Drug Interaction Potential of Dutasteride with Ketoconazole.

Authors:  Seong-Wook Seo; Jin Woo Park; Dong-Gyun Han; Ji-Min Kim; Sanghyun Kim; Taeuk Park; Kyung-Hwa Kang; Min Hye Yang; In-Soo Yoon
Journal:  Pharmaceutics       Date:  2019-12-11       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.